Published in Biochem J on September 15, 2008
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res (2010) 2.30
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods. ChemMedChem (2011) 0.93
PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer (2010) 0.91
Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm (2012) 0.89
Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis. Biochem J (2012) 0.81
Detection and manipulation of phosphoinositides. Biochim Biophys Acta (2014) 0.79
L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ ACS Med Chem Lett (2013) 0.79
Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation. J Mol Model (2014) 0.75
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 8.47
Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 6.26
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 5.80
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell (2000) 5.23
Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med (2005) 5.05
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol (1998) 5.01
PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med (2005) 3.96
Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (2004) 3.47
PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov (2006) 1.85
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem (2004) 1.77
Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun (2003) 1.63
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.62
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem (2006) 1.54
Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol (2005) 1.47
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans (2004) 1.05
Class I phosphoinositide 3-kinases. Int J Biochem Cell Biol (2003) 0.99
Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta). J Mol Model (2006) 0.79
In vitro and in vivo inhibition of rat vascular smooth muscle cell migration and proliferation by a 2-aminochromone U-86983. J Pharmacol Exp Ther (1994) 0.78
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
The antisense transcriptomes of human cells. Science (2008) 6.29
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc (2007) 5.15
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
The predictive capacity of personal genome sequencing. Sci Transl Med (2012) 4.64
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature (2010) 4.53
Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A (2010) 4.47
PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 4.46
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods (2006) 4.21
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res (2007) 4.09